BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.”  SV’s Houman Ashrafian...
BioCentury | Nov 14, 2020

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 7, 2020
Politics, Policy & Law

Where China’s Hatch-Waxman Act falls short: a BioCentury podcast

Long-awaited pharmaceutical provisions included in China’s patent law fall short of what innovators had hoped for, Jones Day’s Tony Chen said on the latest BioCentury This Week – Special Edition podcast.  Chen, a partner in the...
BioCentury | Nov 7, 2020
Politics, Policy & Law

Biden time: 75 days to shape the coming 750 days

There is no time to celebrate or mourn the elections. The United States and the world are on the edge of a precipice and must act quickly to avoid disaster. It is reasonable to assume that...
BioCentury | Nov 4, 2020
Politics, Policy & Law

China’s Hatch-Waxman Act: Not there yet

On Oct. 17, China amended its patent law and introduced patent linkage and patent term extension to strengthen protection of pharmaceutical inventions. Unfortunately, the long-awaited changes are unlikely...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

Luciano Rossetti will retire at year-end from Merck KGaA (Xetra:MRK) after a six-year tenure as global head of R&D for the healthcare business sector. Rossetti’s successors are Danny Bar-Zohar, who will join the organization on Nov. 1 as global head...
BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut. The biotech, which emerged...
BioCentury | Oct 13, 2020

Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders

Swiss newco Chord launched with $16 million to develop an established multiple sclerosis drug in orphan autoimmune indications in a deal that reunites Omega Funds with former Wilson CSO Tom Plitz.  Omega Funds was the...
BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

The Nobel Prize in Chemistry for CRISPR-based gene editing, announced this week, arrives at a time that’s likely to be just chapter one in the field’s history, with the first CRISPR tools yet...
Items per page:
1 - 10 of 5483